On August 24, 2021, ICER released a revised version of a final evidence report from 2018 evaluating the clinical and cost effectiveness of three emerging treatments for hereditary angioedema. Unfortunately, while ICER tried to update its analysis — supposedly to incorporate real-world data — they made no effort to address the flaws in its underlying methodology. As a result, there is ample reason to doubt the value and credibility of the report’s conclusions, which, not surprisingly, recommended increased discounts for the three medications.
Click here to read PAAP’s Last Word on hereditary angioedema treatments.
Click here to read additional commentary and analysis from PAAP Advisor Dr. Paul Langley.